Evidence map›Paper›PMID 25366117›Full record

ArticleNature communications2014

NF-κB-induced KIAA1199 promotes survival through EGFR signalling.

Kateryna Shostak, Xin Zhang, Pascale Hubert, Serkan Ismail Göktuna, Zheshen Jiang, Iva Klevernic, Julien Hildebrand, Patrick Roncarati, Benoit Hennuy, Aurélie Ladang and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The crucial role of CEMIP in cancer metastasis: Mechanistic insights and clinical implications.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Kateryna Shostak1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Xin Zhang1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Pascale Hubert1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Experimental Pathology, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Cancer, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Serkan Ismail Göktuna1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Zheshen Jiang1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Iva Klevernic1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Julien Hildebrand1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Patrick Roncarati1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Experimental Pathology, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Cancer, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Benoit Hennuy1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] GIGA Transcriptomics Facility, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Aurélie Ladang1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Joan Somja1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Experimental Pathology, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Cancer, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
André Gothot1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] GIGA-Infection, Immunity and Inflammation, Department of Medicine/Hematology, University of Liege, CHU, Sart-Tilman, Liege 4000, Belgium.
Pierre Close1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Philippe Delvenne1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Experimental Pathology, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Cancer, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
Alain Chariot1] Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [2] Laboratory of Medical Chemistry, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [3] GIGA-Signal Transduction, University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium [4] Walloon Excellence in Life Sciences and Biotechnology (WELBIO) , University of Liege, 1, Avenue de l'ho^pital, CHU, Sart-Tilman, Liege 4000, Belgium.
University of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Constitutive activation of EGFR- and NF-κB-dependent pathways is a hallmark of cancer, yet signalling proteins that connect both oncogenic cascades are poorly characterized. Here we define KIAA1199 as a BCL-3- and p65-dependent gene in transformed keratinocytes. KIAA1199 expression is enhanced on human papillomavirus (HPV) infection and is aberrantly expressed in clinical cases of cervical (pre)neoplastic lesions. Mechanistically, KIAA1199 binds Plexin A2 and protects from Semaphorin 3A-mediated cell death by promoting EGFR stability and signalling. Moreover, KIAA1199 is an EGFR-binding protein and KIAA1199 deficiency impairs EGF-dependent Src, MEK1 and ERK1/2 phosphorylations. Therefore, EGFR stability and signalling to downstream kinases requires KIAA1199. As such, KIAA1199 promotes EGF-mediated epithelial-mesenchymal transition (EMT). Taken together, our data define KIAA1199 as an oncogenic protein induced by HPV infection and constitutive NF-κB activity that transmits pro-survival and invasive signals through EGFR signalling.

Indexed as

B-Cell Lymphoma 3 ProteinCell SurvivalEpidermal Growth FactorEpithelial-Mesenchymal TransitionErbB ReceptorsHeLa CellsHumansHyaluronoglucosaminidaseKeratinocytesLysosomesMCF-7 CellsPapillomavirus InfectionsProteinsProto-Oncogene ProteinsSemaphorin-3ATranscription Factor RelAB-Cell Lymphoma 3 ProteinBCL3 protein, humanCEMIP protein, humanEpidermal Growth FactorErbB ReceptorsHyaluronoglucosaminidaseProteinsProto-Oncogene ProteinsSEMA3A protein, humanSemaphorin-3ATranscription Factor RelATranscription Factors

Identifiers

PMID25366117
PMCPMC4241993
OpenAlexW2144522854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.